Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
GPCR Structure Therapeutics	$19.53 -0.4%	$22.00	$13.22 ▼ $45.37	$1.12B	-1.87	817,490 shs	527,991 shs
PROK ProKidney	$3.52 -5.6%	$1.28	$0.46 ▼ $7.13	$1.09B	1.26	3.58 million shs	7.43 million shs
PVLA Palvella Therapeutics	$31.23 +9.9%	$23.91	$7.25 ▼ $31.36	$314.20M	-0.11	123,503 shs	469,273 shs
WVE WAVE Life Sciences	$8.01 +2.4%	$6.79	$5.04 ▼ $16.74	$1.22B	-1.01	1.32 million shs	1.15 million shs

7 Stocks to Buy And Hold Forever

Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
GPCR Structure Therapeutics	+1.92%	+2.62%	-4.72%	-9.93%	-56.11%
PROK ProKidney	+10.68%	-14.06%	+278.18%	+371.61%	+54.77%
PVLA Palvella Therapeutics	+2.60%	+10.16%	+21.35%	+16.67%	+2,841,999,900.00%
WVE WAVE Life Sciences	+1.43%	+1.56%	+14.16%	+32.09%	+30.55%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
GPCR Structure Therapeutics	2.9292 of 5 stars	3.5	3.0	0.0	3.2	1.7	0.6
PROK ProKidney	3.383 of 5 stars	3.2	4.0	0.0	3.1	3.3	0.6
PVLA Palvella Therapeutics	2.5359 of 5 stars	3.6	0.0	0.0	2.0	2.5	0.6
WVE WAVE Life Sciences	4.5207 of 5 stars	3.5	2.0	4.8	2.5	4.2	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
GPCR Structure Therapeutics	3.00	Buy	$76.17	290.00% Upside
PROK ProKidney	2.40	Hold	$6.25	77.56% Upside
PVLA Palvella Therapeutics	3.13	Buy	$46.29	48.21% Upside
WVE WAVE Life Sciences	2.92	Moderate Buy	$20.15	151.61% Upside

Current Analyst Ratings Breakdown

Latest PVLA, PROK, WVE, and GPCR Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/16/2025	WVE WAVE Life Sciences	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$16.00
7/15/2025	PROK ProKidney	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$4.00 ➝ $8.00
7/14/2025	PROK ProKidney	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$6.00 ➝ $7.00
7/9/2025	PROK ProKidney	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$6.00 ➝ $9.00
6/30/2025	PROK ProKidney	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Neutral ➝ Underperform	$3.00 ➝ $1.00
6/23/2025	GPCR Structure Therapeutics	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight	$65.00
6/23/2025	GPCR Structure Therapeutics	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Outperform ➝ Market Outperform	$89.00
6/23/2025	WVE WAVE Life Sciences	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform	$18.00
6/11/2025	WVE WAVE Life Sciences	Raymond James Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform	$14.00
5/16/2025	PVLA Palvella Therapeutics	Canaccord Genuity Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$53.00 ➝ $52.00
5/12/2025	GPCR Structure Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$80.00 ➝ $75.00

(Data available from 7/17/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
GPCR Structure Therapeutics	N/A	N/A	N/A	N/A	$15.10 per share	N/A
PROK ProKidney	$80K	12,878.80	N/A	N/A	($3.41) per share	-1.03
PVLA Palvella Therapeutics	$42.81M	8.07	N/A	N/A	$5.58 per share	5.60
WVE WAVE Life Sciences	$108.30M	11.51	N/A	N/A	$1.37 per share	5.85

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
GPCR Structure Therapeutics	-$122.53M	-$0.87	N/A	N/A	N/A	N/A	-16.35%	-15.71%	8/6/2025 (Estimated)
PROK ProKidney	-$61.19M	-$0.60	N/A	N/A	N/A	N/A	N/A	-15.03%	8/8/2025 (Estimated)
PVLA Palvella Therapeutics	-$17.43M	-$12.10	N/A	N/A	N/A	N/A	-60.29%	-43.30%	8/13/2025 (Estimated)
WVE WAVE Life Sciences	-$97.01M	-$0.84	N/A	N/A	N/A	N/A	-86.49%	-37.20%	8/14/2025 (Estimated)

Latest PVLA, PROK, WVE, and GPCR Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/14/2025	Q2 2025	GPCR Structure Therapeutics	-$0.28	N/A	N/A	N/A	N/A	N/A
8/14/2025	Q2 2025	WVE WAVE Life Sciences	-$0.28	N/A	N/A	N/A	N/A	N/A
8/13/2025	Q2 2025	PVLA Palvella Therapeutics	-$0.81	N/A	N/A	N/A	N/A	N/A
8/8/2025	Q2 2025	PROK ProKidney	-$0.14	N/A	N/A	N/A	N/A	N/A
5/15/2025	Q1 2025	PVLA Palvella Therapeutics	-$3.40	-$0.74	+$2.66	-$0.74	N/A	N/A
5/12/2025	Q1 2025	PROK ProKidney	-$0.16	-$0.13	+$0.03	-$0.13	N/A	$0.23 million
5/8/2025	Q1 2025	GPCR Structure Therapeutics	-$0.24	-$0.27	-$0.03	-$0.27	N/A	N/A
5/8/2025	Q1 2025	WVE WAVE Life Sciences	-$0.27	-$0.29	-$0.02	-$0.29	$11.65 million	$9.18 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
GPCR Structure Therapeutics	N/A	N/A	N/A	N/A	N/A
PROK ProKidney	N/A	N/A	N/A	N/A	N/A
PVLA Palvella Therapeutics	N/A	N/A	N/A	N/A	N/A
WVE WAVE Life Sciences	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
GPCR Structure Therapeutics	N/A	23.29	23.29
PROK ProKidney	N/A	10.96	10.96
PVLA Palvella Therapeutics	N/A	8.84	8.84
WVE WAVE Life Sciences	N/A	2.95	2.95

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
GPCR Structure Therapeutics	91.78%
PROK ProKidney	51.59%
PVLA Palvella Therapeutics	40.11%
WVE WAVE Life Sciences	89.73%

Insider Ownership

Company	Insider Ownership
GPCR Structure Therapeutics	9.43%
PROK ProKidney	41.49%
PVLA Palvella Therapeutics	20.50%
WVE WAVE Life Sciences	23.98%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
GPCR Structure Therapeutics	136	57.34 million	51.94 million	Optionable
PROK ProKidney	3	292.70 million	171.26 million	Optionable
PVLA Palvella Therapeutics	N/A	11.06 million	8.79 million	N/A
WVE WAVE Life Sciences	240	155.56 million	118.26 million	Optionable

PVLA, PROK, WVE, and GPCR Headlines

Recent News About These Companies

Breaking Down WAVE Life Sciences: 4 Analysts Share Their Views

July 16 at 6:40 PM | benzinga.com

Citigroup Initiates Coverage of Wave Life Sciences (WVE) with Buy Recommendation

July 16 at 6:40 PM | msn.com

WAVE Life Sciences (NASDAQ:WVE) Shares Gap Up - Should You Buy?

July 16 at 10:59 AM | marketbeat.com

WAVE Life Sciences (NASDAQ:WVE) Coverage Initiated at Citigroup

July 16 at 8:37 AM | marketbeat.com

Wave Life Sciences Unveils Promising Preclinical Data for Obesity Treatment WVE-007 at ADA Scientific Sessions

July 15 at 12:03 AM | msn.com

WAVE Life Sciences (NASDAQ:WVE) Shares Down 6.5% - What's Next?

July 15 at 4:23 PM | marketbeat.com

Leerink Partners Reiterates a Buy Rating on Wave Life Sciences (WVE), Keeps the PT at $24

July 11, 2025 | msn.com

NASDAQ:WVE Financials | Wave Life Sciences Ltd - Investing.com

July 11, 2025 | investing.com

WAVE Life Sciences (NASDAQ:WVE) Trading Up 6.8% - Should You Buy?

July 9, 2025 | marketbeat.com

Brokerages Set WAVE Life Sciences Ltd. (NASDAQ:WVE) PT at $20.50

July 9, 2025 | americanbankingnews.com

WAVE Life Sciences Ltd. Company & People | WVE | Barron's

July 7, 2025 | barrons.com

Wave Life Sciences: Upgrading Rating To Buy After Turbulent 10 Months

July 7, 2025 | seekingalpha.com

Wave Life Sciences: Speculative, But Promising

July 7, 2025 | seekingalpha.com

Wave Life Sciences Ltd. (WVE) - Yahoo Finance

July 6, 2025 | finance.yahoo.com

WAVE Life Sciences Ltd. (NASDAQ:WVE) Given Consensus Rating of "Moderate Buy" by Brokerages

July 6, 2025 | marketbeat.com

WAVE Life Sciences Ltd. (NASDAQ:WVE) Receives Consensus Recommendation of "Moderate Buy" from Analysts

July 6, 2025 | marketbeat.com

Moody Aldrich Partners LLC Increases Holdings in WAVE Life Sciences Ltd. (NASDAQ:WVE)

July 4, 2025 | marketbeat.com

H.C. Wainwright Reaffirms Buy Rating on Wave Life Sciences After ADA Data Release

July 3, 2025 | msn.com

Where WAVE Life Sciences Stands With Analysts

June 23, 2025 | benzinga.com

WAVE Life Sciences (NASDAQ:WVE) Receives "Outperform" Rating from Wedbush

June 23, 2025 | marketbeat.com

Wave Life Sciences Announces Oral Presentation of Preclinical Data Supporting WVE-007's Mechanism (INHBE) to Reduce Fat, Preserve Muscle, and Induce Healthy Weight Loss at ADA ...

June 22, 2025 | manilatimes.netM

New MarketBeat Followers Over Time

Media Sentiment Over Time

PVLA, PROK, WVE, and GPCR Company Descriptions

Structure Therapeutics NASDAQ:GPCR

$19.53 -0.07 (-0.36%)

Closing price 04:00 PM Eastern

Extended Trading

$19.90 +0.37 (+1.89%)

As of 07:55 PM Eastern

Structure Therapeutics Inc., a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company's lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity. It is also developing oral small molecule therapeutics targeting other GPCRs for the treatment of pulmonary and cardiovascular diseases, including ANPA-0073, a biased agonist for apelin receptor, a GPCR that has been implicated in idiopathic pulmonary fibrosis (IPF); and LTSE-2578, an investigational oral small molecule lysophosphatidic acid 1 receptor antagonist for the treatment of IPF and PPF. The company was formerly known as ShouTi Inc. Structure Therapeutics Inc. was incorporated in 2016 and is headquartered in South San Francisco, California.

ProKidney NASDAQ:PROK

$3.52 -0.21 (-5.63%)

Closing price 04:00 PM Eastern

Extended Trading

$3.56 +0.04 (+0.99%)

As of 07:59 PM Eastern

ProKidney Corp., a clinical-stage biotechnology company, provides transformative proprietary cell therapy platform for treating various chronic kidney diseases in the United States. The company's lead product is Renal Autologous Cell Therapy (REACT), an autologous homologous cell admixture, which has completed Phase I clinical trial for REACT in patients with congenital anomalies of the Kidney and Urinary Tract (CAKUT), as well as in Phase III and Phase II clinical trials for the treatment of moderate to severe diabetic kidney disease. ProKidney Corp. founded in 2015 and is headquartered in Winston-Salem, North Carolina.

Palvella Therapeutics NASDAQ:PVLA

$31.23 +2.81 (+9.89%)

As of 04:00 PM Eastern

Palvella Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare genetic skin diseases. Palvella Therapeutics Inc., formerly known as Pieris Pharmaceuticals Inc., is based in WAYNE, Pa.

WAVE Life Sciences NASDAQ:WVE

$8.01 +0.19 (+2.43%)

Closing price 04:00 PM Eastern

Extended Trading

$8.02 +0.01 (+0.12%)

As of 07:22 PM Eastern

Wave Life Sciences Ltd., a clinical-stage biotechnology company, designs, develops, and commercializes ribonucleic acid (RNA) medicines through PRISM, a discovery and drug development platform. The company's RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. It is developing WVE-006, a RNA editing oligonucleotide for the treatment of alpha-1 antitrypsin deficiency; siRNA clinical candidate for the treatment of obesity and other metabolic disorders; WVE-N531, a exon skipping oligonucleotide for the treatment of duchenne muscular dystrophy; and WVE-003, an antisense silencing oligonucleotide for the treatment of Huntington's disease (HD). The company has collaboration agreements with GlaxoSmithKline for the research, development, and commercialization of oligonucleotide therapeutics; Takeda Pharmaceutical Company Limited for the research, development, and commercialization of oligonucleotide therapeutics for disorders of the Central Nervous System; and Asuragen, Inc. for the development and potential commercialization of companion diagnostics for investigational allele-selective therapeutic programs targeting HD. Wave Life Sciences Ltd. was incorporated in 2012 and is based in Singapore.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time